The imidazoline I2-site ligands BU 224 and 2-BFI inhibit MAO-A and MAO-B activities, hydrogen peroxide production, and lipolysis in rodent and human adipocytes

被引:23
作者
Bour, Sandy
Iglesias-Osma, Maria-Carmen
Marti, Luc
Duro, Piedad
Garcia-Barrado, Maria-Jose
Pastor, Maria-Francisca
Prevot, Danielle
Visentin, Virgile
Valet, Philippe
Moratinos, Julio
Carpene, Christian
机构
[1] Univ Toulouse 3, CHU Rangueil, INSERM U586, IFR 31,Unite Rech Obesites, F-31432 Toulouse 4, France
[2] Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain
[3] Univ Salamanca, Fac Farm, Dept Fisiol & Farmacol, E-37007 Salamanca, Spain
关键词
imidazoline site ligand; insulin; MAO (monoamine oxidase); SSAO (semicarbazide-sensitive amine oxidase); adipose tissue;
D O I
10.1016/j.ejphar.2006.09.021
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Numerous imidazolinic agents exhibit antihyperglycaemic properties and have been described to promote insulin secretion, however their effects on adipose tissue development have been poorly investigated. Since white adipose tissue (WAT) plays an important role in glucose homeostasis and expresses imidazoline (I-2) binding sites abundantly, this work aimed at studying extrapancreatic actions of two I-2-site ligands, BU 224 and 2-BFI in adipocytes. Interaction with monoamine oxidase (MAO) was, investigated by measuring the ability to modulate [C-14]tyramine oxidation and hydrogen peroxide production. Direct influence on glucose uptake or on lipolytic activity was tested on mouse, rat, rabbit and human adipocytes. BU 224 and 2-BFI behaved as reversible inhibitors of both MAO-A and -B, as demonstrated by total inhibition of tyramine oxidation in human. adipocytes and platelets. or in liver from rats previously treated with selective MAO-inhibitors. Moreover, they weakly inhibited semicarbazide-sensitive amine oxidase. Like classical MAO-inhibitors, they were unable to produce hydrogen peroxide and to activate glucose uptake but prevented tyramine to do so in rodent, or human, adipocytes. BU 224 and 2-BFI also differed from MAO-inhibitors since they inhibited lipolysis at millimolar concentrations via a still undefined pathway independent of alpha(2)-adrenoceptor stimulation, beta-adrenergic antagonism and MAO activation. However, chronic treatment of obese Zucker rats with 2-BFI did not modify the maximal lipolytic capacity or the mild insulin resistance status of their adipocytes. Taken together, our observations demonstrate on WAT novel effects of BU 224 and 2-BFI different from their already reported actions on brain or endocrine pancreas. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:20 / 30
页数:11
相关论文
共 47 条
[31]  
Morin N, 2001, J PHARMACOL EXP THER, V297, P563
[32]   The elusive family of imidazoline binding sites [J].
Parini, A ;
Moudanos, CG ;
Pizzinat, N ;
Lanier, SM .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1996, 17 (01) :13-16
[33]   Effect of the new imidazoline derivative S-22068 (PMS 847) on insulin secretion in vitro and glucose turnover in vivo in rats [J].
Pelé-Tounian, A ;
Chan, SLF ;
Rondu, F ;
Le Bihan, G ;
Giroix, MH ;
Lamouri, A ;
Touboul, E ;
Pfeiffer, B ;
Manechez, D ;
Renard, P ;
Guardiola-Lemaître, B ;
Godfroid, JJ ;
Pénicaud, L ;
Morgan, NG ;
Ktorza, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 377 (01) :81-87
[34]   High expression of monoamine oxidases in human white adipose tissue:: Evidence for their involvement in noradrenaline clearance [J].
Pizzinat, N ;
Marti, L ;
Remaury, A ;
Leger, F ;
Langin, D ;
Lafontan, M ;
Carpéné, C ;
Parini, A .
BIOCHEMICAL PHARMACOLOGY, 1999, 58 (11) :1735-1742
[35]   Relationship between imidazoline/guanidinium receptive sites and monoamine oxidase A and B [J].
Raddatz, R ;
Lanier, SM .
NEUROCHEMISTRY INTERNATIONAL, 1997, 30 (01) :109-117
[36]  
Raddatz R, 2000, J PHARMACOL EXP THER, V292, P1135
[37]   IMIDAZOLINIC RADIOLIGANDS FOR THE IDENTIFICATION OF HAMSTER ADIPOCYTE ALPHA-2-ADRENOCEPTORS [J].
SAULNIERBLACHE, JS ;
CARPENE, C ;
LANGIN, D ;
LAFONTAN, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 171 (2-3) :145-157
[38]  
SCHULZ A, 1989, N-S ARCH PHARMACOL, V340, P321
[39]   LOCALIZATION OF I-2-IMIDAZOLINE BINDING-SITES ON MONOAMINE OXIDASES [J].
TESSON, F ;
LIMONBOULEZ, I ;
URBAN, P ;
PUYPE, M ;
VANDEKERCKHOVE, J ;
COUPRY, I ;
POMPON, D ;
PARINI, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (17) :9856-9861
[40]   Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X [J].
Velliquette, RA ;
Kossover, R ;
Previs, SE ;
Ernsberger, P .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2006, 372 (04) :300-312